Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?

被引：0
|
作者：
Gerratana, Lorenzo
Davis, Andrew A.
Foffano, Lorenzo
Reduzzi, Carolina
Podany, Emily L.
Medford, Arielle J.
Clifton, Katherine
Velimirovic, Marko
Putur, Annika
Munoz-Arcos, Laura Sofia
Pontolillo, Letizia
Tapiavala, Shaili
Molteni, Elisabetta
Nicolo, Eleonora
Gradishar, William John
Ma, Cynthia X.
Andreopoulou, Eleni
Puglisi, Fabio
Bardia, Aditya
Cristofanilli, Massimo
机构：
[1] Univ Udine, Dept Med DMED, Aviano, Italy
[2] Washington Univ St Louis, St Louis, MO USA
[3] Univ Udine, Udine, Italy
[4] Weill Cornell Med, New York, NY USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Cleveland Clin, Cleveland, OH USA
[8] Massachusetts Gen Hosp, Boston, MA USA
[9] Northwestern Univ, Div Hematol & Oncol, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[10] Univ Udine, Dept Med DAME, Udine, Italy
[11] Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Medica, IRCCS, Udine, Italy
[12] UCLA Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor
    Wang, Biyun
    You, Shuhui
    Xie, Yizhao
    Ji, Mengjing
    Yang, Zhongyi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Methylation differences in breast tumor DNA from African American and European women are predominant in estrogen receptor (ER) negative breast cancer and are associated with childbearing
    Espinal, Allyson C.
    Wang, Dan
    Sucheston-Campbell, Lara
    Liu, Song
    Hu, Qiang
    Tang, Li
    Zirpoli, Gary
    Khoury, Thaer
    Yao, Song
    Demissie, Kitaw
    Bandera, Elisa V.
    Ambrosone, Christine B.
    Higgins, Michael J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)
  • [33] Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Zhu, Li
    Diego, Emilia J.
    Johnson, Ronald R.
    Soran, Atilla
    Dabbs, David J.
    Clark, Beth Z.
    Puhalla, Shannon L.
    Jankowitz, Rachel C.
    Brufsky, Adam M.
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 150 (01) : 34 - 42
  • [34] Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study
    Li, Xuelu
    Lu, Jiawei
    Zhang, Lanxin
    Luo, Yaoting
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 321 - 328
  • [35] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
    Bauer, Katrina R.
    Brown, Monica
    Cress, Rosemary D.
    Parise, Carol A.
    Caggiano, Vincent
    CANCER, 2007, 109 (09) : 1721 - 1728
  • [36] In pre-trastuzumab era estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-positive invasive breast cancer (BC) had a poorer prognosis compared to BC with triple-negative phenotype
    De Matteis, E.
    Cortesi, L.
    Ruscelli, S.
    Messinese, S.
    Cervo, G.
    Cirilli, C.
    Federico, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 51 - 51
  • [37] Unraveling the influence of progesterone receptor status on endocrine therapy sensitivity: insight from epigenetic and fragmentomics ctDNA profiling in estrogen receptor positive, HER2 negative metastatic breast cancer (MBC)
    Foffano, Lorenzo
    Molteni, Elisabetta
    Dri, Arianna
    Franzoni, Alessandra
    Cucciniello, Linda
    Da Ros, Lucia
    Buriolla, Silvia
    Bolzonello, Silvia
    Noto, Claudia
    Russo, Stefania
    Spazzapan, Simon
    Nascimbeni, Elena
    Pasto, Brenno
    Targato, Giada
    Della Rossa, Serena
    Bonotto, Marta
    Minisini, Alessandro Marco
    Damante, Giuseppe
    Belletti, Barbara
    Gerratana, Lorenzo
    Puglisi, Fabio
    CANCER RESEARCH, 2024, 84 (09)
  • [38] Androgen receptor (AR) is more widely expressed then estrogen receptor ( ER) on circulating epithelial tumor cells (CETCs) from breast cancer patients and may be a therapeutic target especially in ER-negative tumors.
    Pizon, M.
    Schott, D.
    Lux, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 180 - 181
  • [39] Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy
    Giuliani, S.
    Leonardi, E.
    Aldovini, D.
    Bernardi, D.
    Pelegrini, M.
    Soli, F.
    Ferro, A.
    Palma, P. Dala
    Decarli, N.
    Barbareschi, M.
    PATHOLOGICA, 2012, 104 (03) : 93 - 97
  • [40] Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer
    Bihani, Teeru
    Jung, JungAh
    Patel, Hitisha K.
    Bardia, Aditya
    Kabos, Peter
    Kaklamani, Virginia
    Jager, Agnes
    Aftimos, Philippe
    Wilks, Sharon
    de Vries, Elisabeth
    Harb, Wael
    Richards, Donald
    Weise, Amy
    Wesolowski, Robert
    van Oordt, Catharina C. W. Menke-van der Houven
    Conkling, Paul
    Neven, Patrick
    Conlan, Maureen G.
    CANCER RESEARCH, 2020, 80 (04)
12345